Israel's Prolor Biotech said recently that it has inked an evaluation and option agreement with Yeda Research and Development, the tech-transfer arm of the Weizmann Institute of Science.

Under the agreement, Prolor, located in the Weizmann Science Park in Nes-Ziona, has the option to obtain from Yeda a license to develop a number of peptide drug candidates, including an anti-obesity peptide, using a delivery technology developed at the Weizmann Institute.

Additional details of the agreement were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.